Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have earned an average rating of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $10.80.

RGLS has been the topic of a number of research reports. StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th. Canaccord Genuity Group lifted their target price on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Oppenheimer reiterated an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a research note on Wednesday, August 14th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research note on Tuesday.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. NEA Management Company LLC acquired a new position in Regulus Therapeutics during the 1st quarter worth approximately $18,627,000. RA Capital Management L.P. acquired a new position in Regulus Therapeutics during the first quarter worth $18,000,000. CVI Holdings LLC purchased a new position in Regulus Therapeutics in the first quarter worth $4,050,000. Vanguard Group Inc. lifted its holdings in Regulus Therapeutics by 158.4% in the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after acquiring an additional 453,784 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Regulus Therapeutics during the 2nd quarter worth $352,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Trading Down 9.4 %

Shares of NASDAQ:RGLS opened at $1.55 on Friday. The firm has a 50 day simple moving average of $1.61 and a 200-day simple moving average of $2.00. Regulus Therapeutics has a twelve month low of $1.08 and a twelve month high of $3.79. The company has a market capitalization of $101.47 million, a PE ratio of -1.06 and a beta of 1.62.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.17). As a group, equities research analysts predict that Regulus Therapeutics will post -0.8 EPS for the current fiscal year.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.